Key Takeaways
- Revenue down 6.6% YoY on price, not volume: API volumes grew ~10% YoY domestically, but a sharp rate correction, especially a fresh price cut in September, pulled the topline lower.
- Margin recovery stalled by a September surprise: Gross margins were improving ~150 bps through August, but a new, unexpected price cut in September left the quarter with only a marginal gain, delaying the anticipated inventory normalization benefit.
- Export weakness is the new, unmodeled headwind: Sluggish demand from key geographies, driven by USD shortages, high interest rates, and geopolitical caution, is a factor management did not account for in its original 10% growth guidance.
- The USFDA overhang is clearing, but the clock is ticking: The FDA has deemed the company's response complete, but has not yet instructed its Indian counterparts to schedule an audit; management was told to follow up by end of October or early November.
- What to watch next quarter: Whether the Tarapur and Salicylic acid projects ramp on schedule, any movement on the USFDA audit, and if export demand stabilizes enough to salvage the revised 5-10% full-year growth target.
The Price-Versus-Volume Disconnect
- Volumes are healthy, but realizations are not: API segment volumes grew approximately 10% YoY, driven by domestic demand, yet segment revenue declined 6.2% due to a downward rate variance that overwhelmed the volume gains.
- A fresh price cut in September reset expectations: Raw material prices had stabilized from February, but prices for inputs to some antibiotic and anti-diabetic products fell further in the last two months, triggering a new, unanticipated selling price cut in September that erased most of the quarter's margin progress.
- Inventory lag amplifies the pain: With 94-95 days of inventory, the P&L impact of falling raw material costs lags, causing a slight decrease in gross margins even as input costs drop, because selling prices fall faster in percentage terms.
- QoQ rate of decline is slowing, but still negative: Management's rough estimate is for a further ~3% negative price rate growth in the December quarter relative to the September quarter.
Adhish Patil: "the thing is, in the month of September there was some price cuts, and because there was a price cut, that was a new price cut which was not there before. So, if that price cut did not happen then with all the high-cost inventory would have been already considered in this quarter itself, nothing would have left."
Export Demand: The Unmodeled Headwind
- A new factor that broke the guidance: Management explicitly stated that export market weakness was not accounted for when it gave the original ~10% growth guidance, and it is the primary reason the full-year target is now under pressure.
- Macro pressures are global and multifaceted: Demand is sluggish due to USD shortages in some geographies, increased interest rates making inventory carrying more expensive for customers, and cautious spending amid geopolitical tensions.
- Recovery is tied to geopolitics, not company action: Management views the export slowdown as temporary, but its recovery speed depends entirely on an improvement in the geopolitical situation, over which the company has no control.
Adhish Patil: "the export market is a new factor which we did not account for when we gave the guidance of around 10%. So, that has impacted our guidance. The September quarter was weak. Right now still all these because of geopolitical tensions things look little dicey."
Margin Walk: A Recovery Interrupted
- The first two months were on track: Gross margins in both the API and Specialty Chemicals businesses improved by almost 150 basis points through July and August, driven by operational efficiency and input cost stabilization.
- September's price cut wiped out most of the gain: The new, unexpected price cut meant high-cost inventory that would have been flushed through in Q2 was not fully absorbed, leaving the quarter with a gross margin improvement of only ~0.3%.
- Other costs are sticky as a percentage of sales: Other manufacturing costs and administration costs have slightly increased as a percentage of revenue QoQ, simply because selling prices have come down drastically while absolute costs have not.
- The path to 13% EBITDA in H2 is still visible: Management expects to improve EBITDA margin by 1% in the second half of FY24, to around 13%, as high-priced inventory normalizes and process improvements in a few API products take hold.
- The 15% ambition for next year comes with conditions: Reaching a 15% margin requires crude levels not to rise sharply, no significant market volatility, and an easing of geopolitical tensions that currently hamper transaction ease.
Adhish Patil: "One is the crude levels should not go up sharply from here, the current year is still okay, there should not be much volatility in the market. And these geopolitical tensions what are happening right now globally that should ease out, because that will definitely impact business quite a lot in terms of ease of transaction."
Capacity & Projects: Building for a Recovery
- Utilization is stuck at 75% by design: The composite utilization rate reflects constant incremental expansions; each time new capacity is added, the denominator resets. For a few products, utilization has already reached 90%, but newer, less-approved products drag the composite lower.
- Tarapur is finally live, after a pipeline delay: The dermatology project was delayed by a few days due to titanium pipeline leakages that required re-rendering, but commercial production started in October.
- The Salicylic acid project is on deck: Management plans to start commercial batches by December end, with a new production block for a related R&D product to follow on an adjacent land parcel.
- SAYKHA Greenfield is slightly delayed but imminent: The project is now expected to start work by end of January, with commercial production batches following 15-30 days later, around February or end of March.
- Methylamine entry is a captive-led diversification: More than 50% of demand from this new chain will be captive, consumed by Metformin production, with two additional products that other group companies currently procure from outside. Utilization is expected at ~35% in FY25, constrained mainly by process settling.
- New capacity unlocks significant revenue potential: Per an analyst's math, the current Rs. 650 crores run rate is based on 75% utilization, implying a total potential of approximately Rs. 1,000 crores in the longer term, of which roughly one-third could be utilized in FY25.
USFDA Audit: Waiting for the Knock
- The response is complete, the wait is not: After filing a final response in March, management spoke with the FDA, who confirmed the response is complete and no further information is needed. However, the FDA had not yet instructed its Indian counterparts to initiate the audit as of the call.
- A mock audit has de-risked the preparation: Before submitting the final response, the company conducted a week-long mock audit with two ex-USFDA inspectors, and that report was submitted as part of the response package.
- The audit will likely be unannounced: Management was told to follow up by end of October or start of November, but the inspection itself can happen anytime and could be a surprise.
- Post-approval, Europe will kick off faster than the U.S.: A couple of DMFs are actively referred to in ANDAs and will launch upon approval, but Ciprofloxacin from that facility has significant demand in the European market, which will ramp much faster than the U.S.
Adhish Patil: "they said that the response is complete. So, they don't need any more information as far as the response is concerned. However, by that time they had not intimated their Indian counterparts to initiate the audit. But they told us that told us to follow up by the end of October or start of November to check with them again."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue growth | Achieve 5% to 10% growth (revised down from ~10%) | FY24 |
| EBITDA margin improvement | Improve by 1%, reaching ~13% | H2 FY24 |
| Gross contribution improvement | Increase by at least 0.5% to 1% | H2 FY24 |
| Tarapur dermatology project | Commercial production started | October 2023 (achieved) |
| Salicylic acid side project | Start commercial batches | By December end |
| SAYKHA Greenfield project | Start work, then commercial batches 15-30 days later | End of January / February-March |
| Total FY24 CAPEX | Rs. 250 to Rs. 300 crores | FY24 |
| All CAPEX plans (Gujarat, Sayakha, Tarapur) | Completed | H2 FY24 |
| FY25 CAPEX | Not beyond Rs. 150 crores | FY25 |
| Methylamine capacity utilization | ~35% (subject to process settling) | FY25 |
| New capacity utilization (analyst math) | One-third of ~Rs. 1,000 crores potential | FY25 |
| USFDA audit follow-up | Follow up with FDA on audit initiation | End of October / start of November |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Consolidated revenue | ₹642 cr, decline of 6.6% YoY |
| H1FY24 consolidated revenue | ₹1,304 cr, flat YoY (vs ₹1,310 cr) |
| EBITDA | ₹77 cr, vs ₹74 cr YoY |
| EBITDA margin | 12.0% |
| PAT | ₹40 cr |
| PAT margin | 6.2% |
| H1FY24 EBITDA margin | 12.4% |
| H1FY24 PAT | ₹88 cr |
| H1FY24 PAT margin | 6.7% |
| API segment volume growth | ~10% YoY |
| API segment revenue decline | 6.2% YoY, due to downward rate variance |
| Formulation segment revenue | ₹86.6 cr, growth of 5.0% YoY, exports contribution ~49% |
| Standalone revenue | ₹578 cr, decline of 7.6% YoY |
| Standalone domestic revenue growth | ~1% YoY on value basis |
| Standalone exports de-growth | ~20% YoY |
| Net debt | ₹589 cr as on 30 Sep 2023, vs ₹609 cr as on 31 Mar 2023 |
| Net debt-to-equity | 0.49x |
| Net debt to total assets | 0.25x |
| API negative price variation QoQ | (-7.5%), Sep 23 vs Jun 23 quarter |
| API negative price variation YoY | (-16%), Sep 23 vs Sep 22 |
| API QoQ volume growth | ~5% |
| Capacity utilization (existing facilities) | 74%–75%, slightly up vs Jun 23 quarter |
| H1FY24 CAPEX incurred | ₹109 cr |
| FY24 CAPEX guidance | ₹250–300 cr |
| FY25 CAPEX guidance | Not beyond ₹150 cr |
| Revenue growth guidance FY24 | 5% to 10% for the full year |
| Gross margin improvement expected in H2FY24 | 0.5% to 1% improvement in net contribution |
| EBITDA margin guidance H2FY24 | ~13% |
| Inventory days | 94–95 days |
| New capacity additional revenue potential | ₹500–600 cr from FY24 CAPEX |
| New capacity utilization expected in FY25 | ~33% (one-third) |